South Korea Prostaglandin Market Size & Outlook, 2025-2033
South Korea Prostaglandin Market Insights
- Based on Reed Intelligence findings, the South Korea Prostaglandin Market reached USD 8.14 Million in 2024 and is estimated to attain USD 14.63 Million by 2033.
- From 2026 to 2033, the South Korea market is expected to grow at a steady CAGR of 6.81%.
- Within the Application category, Ophthalmology dominated in 2024 in terms of market size contribution.
- Over the forecast period, Obstetrics and gynecology is forecasted to deliver the fastest growth, positioning it as the most lucrative Application segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- South Korea contributed 1.4% to the global Prostaglandin Market size in 2024.
- By 2033, United States is forecasted to remain the largest global market for Prostaglandin Market.
- In Asia Pacific, China is projected to capture the leading share of market size by 2033.
- Among Asia Pacific markets, China is expected to post the fastest growth, reaching USD 112.11 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 8.14 Million |
| Market Size In 2033 | USD 14.63 Million |
| Largest segment | Ophthalmology |
| Units | Revenue in USD Million |
| CAGR | 6.81% (2025-2033) |
| Segmnetation Covered | |
| Application |
|
| Delivery Route |
|
| Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South Korea Prostaglandin Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ophthalmology | XX.x | XX.x | XX.x | 3.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Gastrointestinal diseases | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Obstetrics and gynecology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Other Applications | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Korea Prostaglandin Market Delivery Route 2025-2033 (USD Million)
| Delivery Route | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intravitreal injection | XX.x | XX.x | XX.x | 3.89 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Intracameral injection | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Oral | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Topical | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South Korea Prostaglandin Market Type 2025-2033 (USD Million)
| Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Natural | XX.x | XX.x | XX.x | 5.24 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Synthetic | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
